References in periodicals archive ?
will be presenting a 30-minute scientific presentation entitled "Creating and Using a Physiological Model to Support Development of a GPR119 Agonist Diabetes Therapy.
2) Reduction of Food Consumption via Peripheral Mechanisms 2a) Cannabinoid 1 (CB1) receptor antagonist 2b) GPR119 agonists 2c) Opioid Receptors 2d) PPAR Agonists 2e) Antagonists of Glucocorticoid Receptor (GCCR) 2f) Others
In addition, OSI focuses its development resources on advancing high quality and differentiated development assets, including OSI's IGF-1R/IR inhibitor, OSI-906, and its GPR119 agonist, PSN821, both of which have the potential to be blockbusters, "first-in-class" and/or "best-in-class" and are highly competitive in these much sought after target areas.
The increase in year-to-date revenue is also a result of a full year of revenue recognition under the collaboration agreements with Abbott and Boehringer Ingelheim, for our GnRH and GPR119 programs, respectively.
PSN821, an oral GPR119 agonist being developed for the treatment of type 2 diabetes and PSN602, an oral dual monoamine reuptake inhibitor and 5-HT1A agonist being developed for the treatment of obesity, were discovered by OSI's diabetes and obesity R&D team and are wholly owned by OSI.
4: GPR119 agonists in development for the treatment of type 2 diabetes 82
Nasdaq: OSIP) announced today that it has initiated a first-in-human clinical study for its G-protein coupled receptor GPR119 agonist, PSN821, which the Company is developing for the treatment of type 2 diabetes.
The increase in year-to-date revenue is a result of these milestones, as well as a full nine months of revenue recognition under the collaboration agreements with Abbott and Boehringer Ingelheim, for our GnRH and GPR119 programs, respectively.
Two classes of emerging metabolic approaches stand out from the remainder: the glucose-dependent stimulation of insulin release or secretion by glucokinase activators or direct activation of the GPR119 receptor and the suppression of glucocorticoid action by inhibition of the 11-beta hydroxysteroid dehyrogenase type 1 (HSD-1) or directly of the glucocorticoid receptor.
The increase in revenue from 2010 to 2011 is due to a full period of revenue recognition under the collaboration agreements with Abbott and Boehringer Ingelheim, for our GnRH and GPR119 programs, respectively.
Preclinical data on PSN821, a novel, orally available agonist of the G-protein coupled receptor GPR119, being developed for the treatment of type 2 diabetes and obesity, were presented in an oral presentation.
RE42,190 with claims to methods of identifying compounds that modulate the activity of the GPR119 receptor, a target for identifying small molecules for the treatment of diabetes.
Medical browser ?
Full browser ?